Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELO trial of panitumumab plus trifluridine-tipiracil versus trifluridine-tipiracil in pretreated RAS wild-type metastatic colorectal cancer
2018-001600-12Phase 2Completed
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC) comparing Panitumumab plus trifluridine-tipiracil with Trifluridine-tipiracil alone (2 arms). Primary endpoint: Progression-free survival. Started May 2021; status: completed.
02
Drugs
panitumumabtrifluridine + tipiracil
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2018-001600-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001600-12.